Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer

Journal of Clinical Pharmacology
Leyanis Rodríguez-VeraHelena Colom Codina

Abstract

This study aimed (1) to develop a semimechanistic pharmacokinetic (PK) model for nimotuzumab in patients with advanced breast cancer and (2) to identify demographic, biochemical, and clinical predictive factors of the PK variability. Data from a phase 1 study were analyzed using the nonlinear mixed-effects approach (NONMEM). A target-mediated disposition model that included 2 open PK compartments, the monoclonal antibody (mAb)-target binding, and target and mAb-target complex turnovers best described the linear and nonlinear PK. Covariates had no influence on the PK parameters. The final parameter estimates were 19.93 L (steady-state volume), 0.0045-0.0172 L/h (range of total clearance values), 6.96 μg/mL (steady-state binding constant), 5.50 h(-1) (target degradation rate constant), 1.43 (μg/mL) · h(-1) (complex formation rate), and 0.148 h(-1) (complex internalization rate constant). The model described the effect of the mAb-target binding, and target and mAb-target complex turnovers on nimotuzumab PK. Simulations showed that doses above 200 mg maintained the 50% target occupancy during all of the treatment. This model can be very useful for knowing the dosing schedules required for efficacy and supports further investigation...Continue Reading

References

Sep 1, 1994·Clinical Pharmacology and Therapeutics·G Levy
Dec 1, 1993·Journal of Pharmacokinetics and Biopharmaceutics·M O Karlsson, L B Sheiner
Mar 1, 1997·Immunotechnology : an International Journal of Immunological Engineering·C MateoR Pérez
May 10, 2002·Journal of Pharmacokinetics and Pharmacodynamics·D E Mager, W J Jusko
Dec 20, 2003·Methods and Findings in Experimental and Clinical Pharmacology·N Iznaga-EscobarR Pérez-Rodríguez
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tania CrombetAgustín Lage
May 4, 2005·Cancer Chemotherapy and Pharmacology·Rene BrunoPamela Klein
Sep 24, 2005·Pharmaceutical Research·Donald E Mager, Wojciech Krzyzanski
Feb 14, 2006·Biochemical Pharmacology·Donald E Mager
Dec 22, 2007·Acta Oncologica·Fernando RiveraRaul Marquez
Jan 26, 2008·Journal of Clinical Pharmacology·Nathanael L DirksBernd Meibohm
Nov 14, 2008·Journal of Pharmacokinetics and Pharmacodynamics·Leonid GibianskyPeiming Ma
Sep 3, 2009·Journal of Clinical Pharmacology·Peiming MaAndrew Chow
Nov 27, 2009·Cancer Immunology, Immunotherapy : CII·Miki TonguMamoru Harada
Apr 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Federico RojoJoan Albanell
Apr 28, 2010·International Journal of Clinical Pharmacology and Therapeutics·A A FasanmadeH M Davis
Sep 8, 2010·Clinical Pharmacokinetics·Nathanael L Dirks, Bernd Meibohm
Jan 10, 2013·Clinical Pharmacokinetics·Miroslav DostalekManoranjenni Chetty
Sep 21, 2013·Cancer Chemotherapy and Pharmacology·Wataru OkamotoKazuhiko Nakagawa
Apr 22, 2014·Current Drug Metabolism·Shaojun Shi

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.